Lucid Diagnostics Inc (NASDAQ: LUCD) is a commercial-stage medical diagnostics company that develops and markets tools for early detection of esophageal precancer. Its two core products are EsoGuard, a DNA biomarker test for Barrett's esophagus and related precancerous conditions, and EsoCheck, a swallowable balloon device used to collect esophageal cell samples for EsoGuard testing. Revenue is generated on a per-test, transactional basis, with reimbursement tied to Medicare payment rates set by the Centers for Medicare and Medicaid Services. The company received a U.S. Department of Veterans Affairs contract in January 2026, priced at the established CMS Medicare rate, expanding access through the VA Federal Supply Schedule to facilities serving more than nine million enrolled veterans annually. EsoCheck holds CE Mark certification under MDD and EsoGuard holds CE Mark self-certification under IVDD, permitting marketing in European Economic Area countries. Lucid Diagnostics is a subsidiary of PAVmed Inc. and is headquartered in the United States, relying on contract manufacturers and its own laboratory capacity to process EsoGuard tests.

Revenue model

Per-test revenue from EsoGuard diagnostic tests, with reimbursement tied to Medicare payment rates established by CMS. The VA contract (January 2026) uses pre-negotiated pricing matching the Medicare rate.

Products and services

EsoGuard: a DNA biomarker laboratory test for detection of Barrett's esophagus and esophageal precancer. EsoCheck: a swallowable balloon cell-collection device used to obtain esophageal samples for EsoGuard testing.

Customers and end markets

Healthcare providers including gastroenterologists, primary care physicians, and hospital systems. The U.S. Department of Veterans Affairs (contract awarded January 2026) is a named institutional customer. End market is esophageal precancer screening.

Value-chain role

Lucid Diagnostics develops proprietary diagnostic tests and devices, relies on contract manufacturers for device production, and operates its own laboratory to process EsoGuard tests and generate test reports.

Geographic exposure

Primary operations in the United States. CE Mark certification for EsoCheck (under MDD) and EsoGuard (under IVDD) permits marketing in European Economic Area countries, though international commercial activity is not described in the filing excerpts.

Source: SEC 10-K, filed 2026-03-25

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Daxor Corp Pulse Biosciences Inc enVVeno Medical Corp LENSAR Inc Neuronetics Inc Neuropace Inc Pro-Dex Inc